Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XCEL-MT-OSTEO-ALPHA in Osteonecrosis of the Femoral Head
NCT01605383Phase 2Completed
- Sponsor
- Banc de Sang i Teixits
- Start
- May 2015
- Primary completion
- Apr 2018
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head (ONFH) (2 arms), sponsored by Banc de Sang i Teixits. Primary endpoints: Safety of XCEL-MT-OSTEO-ALPHA at 12 months and Feasibility of XCEL-MT-OSTEO-ALPHA at 12 months. Started May 2015; status: completed.
02
Drugs
XCEL-MT-OSTEO-ALPHA
03
Conditions
osteonecrosis of the femoral head (ONFH)
Beyond the preview
Go deeper on NCT01605383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605383.